A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction
Public ClinicalTrials.gov record NCT02742103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction
Study identification
- NCT ID
- NCT02742103
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- CSL Behring
- Industry
- Enrollment
- 83 participants
Conditions and interventions
Interventions
- CSL_112 Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2016
- Primary completion
- May 31, 2017
- Completion
- May 31, 2017
- Last update posted
- Jun 10, 2020
2016 – 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site 16101 | Birmingham | Alabama | 35211 | — |
| Study Site 16078 | Huntsville | Alabama | 35801 | — |
| Study Site 16168 | Concord | California | 94520 | — |
| Study Site 16130 | Littleton | Colorado | 80120 | — |
| Study Site 16135 | Danbury | Connecticut | 06810 | — |
| Study Site 16003 | Jacksonville | Florida | 32209 | — |
| Study Site 16112 | Boise | Idaho | 83712 | — |
| Study Site 16208 | Alexandria | Louisiana | 71301 | — |
| Study Site 16061 | Petoskey | Michigan | 49770 | — |
| Study Site 16056 | Durham | North Carolina | 27705 | — |
| Study Site 16014 | High Point | North Carolina | 27762 | — |
| Study Site 16018 | Rapid City | South Dakota | 57701 | — |
| Study Site 16241 | Wichita Falls | Texas | 76301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02742103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2020 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02742103 live on ClinicalTrials.gov.